Sienna recent pullback brings good entry point, says BMO Capital
BMO Capital analyst Gary Nachman says Sienna Biopharmaceuticals' key catalysts are getting closer following its Q1 results. The company's important data readouts over the next year, beginning in Q3, include SNA-125 for psoriasis and atopic dermatitis, SNA-001 for light hair removal and acne, and SNA-120 for pruritis, Nachman tells investors in a post-earnings research note. He continues to see a "good risk/reward" on the shares into the data catalysts and remains confident in management's ability to execute. Nachman believes recent pullback in the stock creates a good entry point and reiterates an Outperform rating on Sienna Biopharmaceuticals with a $30 price target.